id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-P-4584-0011,FDA,FDA-2016-P-4584,"Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug
Interactions re Citizen Petition from Public Citizens Health Research Group",Supporting & Related Material,Background Material,2016-12-28T05:00:00Z,2016,12,,,2016-12-28T21:50:35Z,,0,0,090000648243b759
FDA-2016-P-4584-0001,FDA,FDA-2016-P-4584,Citizen Petition from Public Citizens Health Research Group,Other,Citizen Petition,2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,2017-05-31T03:59:59Z,2016-12-28T21:49:56Z,,0,0,090000648243b3c0
FDA-2016-P-4584-0007,FDA,FDA-2016-P-4584,Clopidogrel - 2016-09 re Citizen Petition from Public Citizens Health Research Group,Supporting & Related Material,Background Material,2016-12-28T05:00:00Z,2016,12,,,2016-12-28T21:50:20Z,,0,0,090000648243b755
FDA-2016-P-4584-0008,FDA,FDA-2016-P-4584,Health Canada Warning Repaglinide Jul 2015 re Citizen Petition from Public Citizens Health Research Group,Supporting & Related Material,Background Material,2016-12-28T05:00:00Z,2016,12,,,2016-12-28T21:50:23Z,,0,0,090000648243b756
FDA-2016-P-4584-0006,FDA,FDA-2016-P-4584,Carilion-Prandin Label Aug 2016 re Citizen Petition from Public Citizens Health Research Group,Supporting & Related Material,Background Material,2016-12-28T05:00:00Z,2016,12,,,2016-12-28T21:50:17Z,,0,0,090000648243b754
FDA-2016-P-4584-0004,FDA,FDA-2016-P-4584,Canadian drug label - clopidogrel 2016-06 re Citizen Petition from Public Citizens Health Research Group,Supporting & Related Material,Background Material,2016-12-28T05:00:00Z,2016,12,,,2016-12-28T21:50:11Z,,0,0,090000648243b3c5
FDA-2016-P-4584-0009,FDA,FDA-2016-P-4584,Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction re Citizen Petition from Public Citizens Health Research Group,Supporting & Related Material,Background Material,2016-12-28T05:00:00Z,2016,12,,,2016-12-28T21:50:27Z,,0,0,090000648243b757
FDA-2016-P-4584-0003,FDA,FDA-2016-P-4584,BMS-Plavix Label Sept 2016 re Citizen Petition from Public Citizens Health Research Group,Supporting & Related Material,Background Material,2016-12-28T05:00:00Z,2016,12,,,2016-12-28T21:50:07Z,,0,0,090000648243b3c4
FDA-2016-P-4584-0002,FDA,FDA-2016-P-4584,Acknowledgement Letter from FDA DDM to Public Citizens Health Research Group,Other,Acknowledgement Letter/Receipt,2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,,2016-12-28T21:50:00Z,,0,0,090000648243b3c2
FDA-2016-P-4584-0005,FDA,FDA-2016-P-4584,Canadian drug label - repaglinide 2016-04 re Citizen Petition from Public Citizens Health Research Group,Supporting & Related Material,Background Material,2016-12-28T05:00:00Z,2016,12,,,2016-12-28T21:50:14Z,,0,0,090000648243b753
FDA-2016-P-4584-0010,FDA,FDA-2016-P-4584,Repaglinide - 2016-08 re Citizen Petition from Public Citizens Health Research Group,Supporting & Related Material,Background Material,2016-12-28T05:00:00Z,2016,12,,,2016-12-28T21:50:30Z,,0,0,090000648243b758